本帖最后由 老马 于 2012-1-13 21:20 编辑
) v4 X% w! t$ k# c3 M; q5 |* U. l, |) b6 L4 x3 C @+ I
爱必妥和阿瓦斯丁的比较
+ Q# U: I5 ]+ i: D0 p+ R1 ?
0 Y" n0 p, |2 D% j' X2 p
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/6 v. f5 h9 l, ]. I, C# [, H. J
* }% X/ A$ N4 f8 \$ I' E4 f7 o
. [ D+ w/ R( z6 ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
) X* a# k4 I6 g7 W" P8 e- k==================================================, \/ g9 G7 A( m0 x8 M
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 S* M4 C5 I% R! r% a% |( LPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- h8 H, Q) ^1 d7 A& U: C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.3 c, ^, X: _4 @. T! T+ F
|